<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004799</url>
  </required_header>
  <id_info>
    <org_study_id>199/11953</org_study_id>
    <secondary_id>NBL-SS-19910415</secondary_id>
    <nct_id>NCT00004799</nct_id>
  </id_info>
  <brief_title>Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Bacteriological Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Compare the safety and efficacy of acellular 2-component vs. acellular&#xD;
      multicomponent vs. whole-cell pertussis vaccine vs. placebo in infants living in Sweden.&#xD;
&#xD;
      II. Compare the relative protection of each vaccine against atypical or subclinical pertussis&#xD;
      infection.&#xD;
&#xD;
      III. Analyze possible laboratory correlates to vaccine protection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by&#xD;
      participating institution.&#xD;
&#xD;
      The first group of infants receives a vaccine composed of inactivated pertussis toxin (iPT)&#xD;
      and filamentous hemagglutin (FHA).&#xD;
&#xD;
      The second group receives a vaccine containing iPT, FHA, pertactin, agglutinogen 2, and&#xD;
      agglutinogen 3.&#xD;
&#xD;
      The third group receives a whole-cell pertussis vaccine. The fourth group receives a&#xD;
      diphtheria-tetanus vaccine as the control. All vaccines are given as an intramuscular&#xD;
      injection, at 2-3, 4, and 6 months of age.&#xD;
&#xD;
      Close surveillance of infants and families continues for 2-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1991</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>10000</enrollment>
  <condition>Pertussis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>whole-cell pertussis vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>diphtheria-tetanus vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Population Characteristics--&#xD;
&#xD;
          -  Infants aged 2 months at planned date of first vaccination&#xD;
&#xD;
          -  No prior pertussis confirmed by culture&#xD;
&#xD;
          -  The following do not exclude: Down syndrome Prematurity Healthy babies vaccinated&#xD;
             according to chronological age Recent pertussis exposure Seizures in parent or sibling&#xD;
             Sudden infant death in sibling Close relative with history of anaphylaxis or allergy&#xD;
             Close relative with history of strong reaction to vaccination&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Age: Under 3 months&#xD;
&#xD;
          -  Renal: No renal failure&#xD;
&#xD;
          -  Other: No prior gammaglobulin No requirement for immunosuppressives, e.g., HIV&#xD;
             infection No manifest immunosuppression No serious chronic illness associated with&#xD;
             failure to thrive No cardiac disease No progressive neurologic disease No uncontrolled&#xD;
             epilepsy or infantile spasms No parental language or communication barrier&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Olin</last_name>
    <role>Study Chair</role>
    <affiliation>National Bacteriological Laboratory</affiliation>
  </overall_official>
  <verification_date>January 1997</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>bacterial infection</keyword>
  <keyword>immunologic disorders and infectious disorders</keyword>
  <keyword>pertussis</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

